744 related articles for article (PubMed ID: 26735408)
1. Prospects for gene-engineered T cell immunotherapy for solid cancers.
Klebanoff CA; Rosenberg SA; Restifo NP
Nat Med; 2016 Jan; 22(1):26-36. PubMed ID: 26735408
[TBL] [Abstract][Full Text] [Related]
2. Treating cancer with genetically engineered T cells.
Park TS; Rosenberg SA; Morgan RA
Trends Biotechnol; 2011 Nov; 29(11):550-7. PubMed ID: 21663987
[TBL] [Abstract][Full Text] [Related]
3. Redirected T cells in cancer therapy.
Sangiolo D
Expert Opin Biol Ther; 2015; 15(12):1667-70. PubMed ID: 26515608
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.
Srivastava S; Riddell SR
J Immunol; 2018 Jan; 200(2):459-468. PubMed ID: 29311388
[TBL] [Abstract][Full Text] [Related]
6. Antigen choice in adoptive T-cell therapy of cancer.
Offringa R
Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
[TBL] [Abstract][Full Text] [Related]
7. Engineering T cells for adoptive therapy: outsmarting the tumor.
Kunert A; Debets R
Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
[TBL] [Abstract][Full Text] [Related]
8. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
Yang QY; Yang JD; Wang YS
Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
[TBL] [Abstract][Full Text] [Related]
9. Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.
Leuci V; Mesiano G; Gammaitoni L; Aglietta M; Sangiolo D
Curr Gene Ther; 2014 Feb; 14(1):52-62. PubMed ID: 24365144
[TBL] [Abstract][Full Text] [Related]
10. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
11. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
12. Engineering CAR-T Cells for Improved Function Against Solid Tumors.
Morgan MA; Schambach A
Front Immunol; 2018; 9():2493. PubMed ID: 30420856
[TBL] [Abstract][Full Text] [Related]
13. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
Ikeda H
Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
[TBL] [Abstract][Full Text] [Related]
14. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
Ott PA; Dotti G; Yee C; Goff SL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
[TBL] [Abstract][Full Text] [Related]
15. Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers.
Tay JC; Zha S; Wang S
Immunotherapy; 2017 Dec; 9(16):1339-1349. PubMed ID: 29185393
[TBL] [Abstract][Full Text] [Related]
16. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
17. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
19. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
